Enoxaparin (Inhixa) 60 mg Pre-Filled Syringe x10

Solution for injection in pre-filled syringe. - Clear, colourless to pale yellow solution.

Inhixa is indicated in adults for:
• Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.
•Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.
• Prevention of thrombus formation in extra corporeal circulation during haemodialysis.
•Acute coronary syndrome:
•Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.
•Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).

Features

Available as:
• Inhixa 2,000 IU (20 mg) in 0.2 mL solution for injection in pre-filled syringe

• Inhixa 4,000 IU (40 mg) in 0.4 mL solution for injection in pre-filled syringe
• Inhixa 6,000 IU (60 mg) in 0.6 mL solution for injection in pre-filled syringe
• Inhixa 8,000 IU (80 mg) in 0.8 mL solution for injection in pre-filled syringe
• Inhixa 30,000 IU (300 mg)/3 mL solution for injection in multidose vial

Nature and contents of container:
• a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a blue polypropylene plunger rod. The syringe can be additionally equipped with needle guard; or
• a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a white polycarbonate plunger rod equipped with UltraSafe Passive needle guard.

Special precautions for storage
• Store below 25 °C. Do not freeze.

Shelf life
• Diluted medicinal product with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose - 8 hours